Briefings
March 15, 2010 - The National Call to Action on Cancer Prevention and Survivorship Community hosted the 2010 Workshop: Innovation in the War on Cancer to engage stakeholders from all parts of the cancer community and beyond to help make cancer prevention and survivorship a national priority. The event featured the release of a new paper by Boston Healthcare Associates, Recognizing Value in Oncology Innovation, which describes the evolutionary nature of progress. Participants will also identify actionable ways to leverage innovation to advance the fight against cancer.
CHI's 2009 California Healthcare Policy Forum 2009
November 11, 2009 -
CHI's 2009 California Healthcare Policy Forum highlighted the need for establishing a dialogue between state and federal policy makers, payers and patients on reigning in the cost of medicine and medical technology while protecting innovation and encouraging the future investment needed to drive research and discovery. Videos of many speakers are available here. For example,John C. Martin of Gilead Sciences spoke on the process of innovation in HIV/AIDS treatments.
December 15, 2008 – The “Best and Brightest Forum on Medical Innovation” held in Philadelphia focused attention on the serious challenges facing the United States in maintaining its global leadership position in medical innovation. The event was co-hosted by PhRMA, Pennsylvania Bio, BioAdvance, and Select Greater Philadelphia and featured panelist speakers, including economic leaders, academic scholars, researchers, biopharmaceutical company representatives, education experts, and other stakeholders. During the event, survey research was released, which found that the medical community is concerned about the future of medical innovation in the United States and believes government policy is key to continued success in medical innovation.
Transforming Health: Fulfilling the Promise of ResearchNovember 16, 2007 – The Transforming Health: Fulfilling the Promise of Research conference highlighted cutting-edge medical research in the public and private sectors. The conference brought together leading voices from the private sector, government, academia, and patient communities to discuss how to gain the most from our investment in research and overcome the barriers to integrating new knowledge into better health care for all. A nationally representative poll on Americans’ attitudes about the importance of research and new treatments was also presented at the conference.
December 2006 – The application of comparative and cost-effectiveness analysis to prescription drugs and other health technologies is the subject of growing interest by U.S. policymakers both in Washington, D.C. and in many states. At this conference, policy experts will examine coverage and payment decisions by Australia’s PBAC and the potential impact of a centralized, mandatory cost-effectiveness standard in the United States. **
Live webcast on Friday, December 15, 2006 from 8:00 a.m. to 10:30 a.m. Pacific Time.**
November 2006 – Adaptive clinical trial designs provide a potential pathway for drug development that, under certain circumstances, can improve quality, speed and efficiency of decision making. The aim of this workshop was to establish a constructive dialogue among statisticians, clinicians, regulators and other functions within the pharmaceutical industry, health authority agencies, and academia to contribute to the development of consensus positions in the emerging field of adaptive designs.
October 2006 – The Foundation for the National Institutes of Health, the Food and Drug Administration, the National Institutes of Health, and the Pharmaceutical Research and Manufacturers of America have announced the launch of The Biomarkers Consortium, a public-private research partnership. The consortium will discover, develop, and qualify new biological markers to support new drug development, preventive medicine, and medical diagnostics. Results from consortium projects will be broadly available to researchers worldwide.
Patient Advocacy Groups Briefing
May 2006 - A briefing for patient advocacy groups held in Washington, DC, explored both the process of innovation and the factors that affect how quickly innovation reaches doctors and patients.
A Decade of Innovation
April 2006 - In the last decade, biopharmaceutical companies have made great progress in the fight against rare diseases. Over 160 drugs were approved during the past decade to treat rare or "orphan" diseases, and according to the NIH, there are 6,000-7,000 rare diseases affecting over 25 million Americans.
New Medicines Approved 2005
February 2006 - The Food and Drug Administration approved many innovative medicines in 2005, including 28 entirely new medicines for some of the leading causes of death and illness. This year we are highlighting two of those new drugs at our new approvals briefing on Capitol Hill.
back to top
